Papers/links/findings de revistas científicas.
Abstract The ongoing COVID-19 outbreak expanded rapidly throughout China. Major behavioral, clinical, and state interventions have been undertaken to mitigate the epidemic and prevent the persistence of the virus in human populations in China and worldwide. It remains unclear how these unprecedented interventions, including travel restrictions, affected COVID-19 spread in China. We use real-time mobility data from Wuhan and detailed case data including travel history to elucidate the role of case importation on transmission in cities across China and ascertain the impact of control measures. Early on, the spatial distribution of COVID-19 cases in China was explained well by human mobility data. Following the implementation of control measures, this correlation dropped and growth rates became negative in most locations, although shifts in the demographics of reported cases were still indicative of local chains of transmission outside Wuhan. This study shows that the drastic control measures implemented in China substantially mitigated the spread of COVID-19.
Findings In our baseline scenario, we estimated that the basic reproductive number for 2019-nCoV was 2·68 (95% CrI 2·47–2·86) and that 75 815 individuals (95% CrI 37 304–130 330) have been infected in Wuhan as of Jan 25, 2020. The epidemic doubling time was 6·4 days (95% CrI 5·8–7·1). We estimated that in the baseline scenario, Chongqing, Beijing, Shanghai, Guangzhou, and Shenzhen had imported 461 (95% CrI 227–805), 113 (57–193), 98 (49–168), 111 (56–191), and 80 (40–139) infections from Wuhan, respectively. If the transmissibility of 2019-nCoV were similar everywhere domestically and over time, we inferred that epidemics are already growing exponentially in multiple major cities of China with a lag time behind the Wuhan outbreak of about 1–2 weeks.
#COVIDー19— Comciencia . (@comcienciacrac) March 22, 2020
Uno de los instrumentos más necesarios para salvar la vida a los pacientes son los FÁRMACOS eficaces y seguros. Lamentablemente, a pesar de ya disponer de una buena cantidad de candidatos a la fecha, ninguno dispone de evidencias suficientes #coronavirus #ciencia pic.twitter.com/EGUjuTzz5p
UPCH y FARVET Perú buscan desarrollar una vacuna contra el COVID-19
Europa Lanza clinical trial para probar vacuna
#vacunas— Comciencia . (@comcienciacrac) March 21, 2020
Aún faltan meses para que podamos contar con una vacuna segura contra el COVID-19. A la fecha se han identificado una serie de candidatos para esta vacuna, los cuales han sido resumidos por el equipo de COMCIENCIA en la infografía de hoy.#ciencia #coronavirus #salud pic.twitter.com/dENVitqLmM